Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON), led by Ross Uhrich, “aims to fundamentally change the field of cancer screening by developing first-in-class, over-the-counter, MCED tests that screen for 30+ cancers at Stage 1. POSEIDON intends to develop non-invasive synthetic sensors and reporters to reliably detect cancer from breath or urine samples at home. The self-administered kit, based on human-centered design, would allow any adult American to screen for cancers before symptoms arise. The kit would also integrate results securely with electronic health records and ensure individuals connect with a health care professional via a telemedicine call to review results.” Proposers’ Day (in person in Baltimore) is on September 4.
August 2, 2024